SCHEMBL25949110

SCHEMBL25949110

CCc1cc(C(F)F)nn1-c1nc(Cl)ccc1C(C)=O

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LIMK1 P53667 2/20 0.32
LIMK2 P53671 2/20 0.32
PDE4B Q07343 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25946382 0.87 MEN1 (0.35) LIMK1LIMK2PDE4B
SCHEMBL25949117 0.84 ALDH1A1 (0.34) LIMK1LIMK2PDE4B
SCHEMBL25949125 0.81 PDE4B (0.42) LIMK1LIMK2PDE4B
SCHEMBL25318523 0.78
SCHEMBL31361106 0.78 ALDH1A1 (0.40) LIMK1LIMK2PDE4B
SCHEMBL30508760 0.75 TUBB4A (0.41) LIMK1LIMK2PDE4B
SCHEMBL25316579 0.75 TUBB4A (0.41) LIMK1LIMK2PDE4B
SCHEMBL30508770 0.75 MEN1 (0.41)
SCHEMBL25946388 0.74 MEN1 (0.39)
SCHEMBL25942572 0.73 HSD17B10 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4466258-A1 NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2024-11-27 EP disclosed
US-20240383875-A1 Benzimidazole Pyridine Derivatives HOFFMANN-LA ROCHE INC. (US) 2024-11-21 US disclosed
CN-118591534-A Novel benzimidazole pyridine derivatives 豪夫迈·罗氏有限公司 2024-09-03 CN disclosed
WO-2023139085-A1 NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2023-07-27 WO disclosed
WO-2023139085-A1 NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383875-A1 Benzimidazole Pyridine Derivatives H1-3, H1-2, H1-4 LIMK1 3567/4885LIMK2 3432/4885PDE4B 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.